Literature DB >> 20226525

Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?

Dolors Costa1, Sandra Valera, Ana Carrió, Amparo Arias, Concha Muñoz, María Rozman, Mohamed Belkaid, Rita Coutinho, Benet Nomdedeu, Elias Campo.   

Abstract

Although conventional cytogenetics is considered the gold standard to detect chromosomal abnormalities in myelodysplastic syndromes (MDS), fluorescence in situ hybridization (FISH) is being increasingly used additionally. However, the real contribution of FISH analysis in the cytogenetic diagnosis of MDS has not been well defined. The aim of this study was to evaluate whether FISH studies are able to reveal chromosomal abnormalities in MDS patients undetected by conventional cytogenetics. One hundred seventy-four FISH studies were performed on bone marrow samples of 60 patients with MDS. The number of FISH studies in each patient was variable (1-5). FISH studies confirmed the G-banding cytogenetic findings in 99.4% (153/154) of samples and detected cytogenetic abnormalities in 25% (5/20) of cases in which the conventional cytognetic study failed. These results indicate that FISH studies provide relevant information in MSD in which the conventional cytogenetic analysis was unsuccessful but add little value to a normal katyotype in conventional cytogenetic analysis.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20226525     DOI: 10.1016/j.leukres.2010.02.019

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

1.  Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.

Authors:  Friederike Braulke; Uwe Platzbecker; Catharina Müller-Thomas; Katharina Götze; Ulrich Germing; Tim H Brümmendorf; Florian Nolte; Wolf-Karsten Hofmann; Aristoteles A N Giagounidis; Michael Lübbert; Peter L Greenberg; John M Bennett; Francesc Solé; Mar Mallo; Marilyn L Slovak; Kazuma Ohyashiki; Michelle M Le Beau; Heinz Tüchler; Michael Pfeilstöcker; Thomas Nösslinger; Barbara Hildebrandt; Katayoon Shirneshan; Carlo Aul; Reinhard Stauder; Wolfgang R Sperr; Peter Valent; Christa Fonatsch; Lorenz Trümper; Detlef Haase; Julie Schanz
Journal:  Haematologica       Date:  2014-10-24       Impact factor: 9.941

2.  Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach.

Authors:  Won Kyung Kwon; Jin Young Lee; Yeung Chul Mun; Chu Myong Seong; Wha Soon Chung; Jungwon Huh
Journal:  Korean J Hematol       Date:  2010-09-30

3.  Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.

Authors:  Sara A Monaghan; Lijun Dai; Markus Y Mapara; Daniel P Normolle; Susanne M Gollin; Suzanne Lentzsch
Journal:  Leuk Lymphoma       Date:  2013-01-28

4.  Comparison of Diagnostic Yield of a FISH Panel Against Conventional Cytogenetic Studies for Hematological Malignancies: A South Indian Referral Laboratory Analysis Of 201 Cases

Authors:  Vishal Ashok; Ramya Ranganathan; Smitha Chander; Sharat Damodar; Sunil Bhat; Nataraj K S; Satish Kumar A; Sachin Suresh Jadav; Mahesh Rajashekaraiah; Sundareshan T S
Journal:  Asian Pac J Cancer Prev       Date:  2017-12-29

5.  Comparative assessment of conventional chromosomal analysis and fluorescence in situ hybridization in the evaluation of suspected myelodysplastic syndromes: a single institution experience.

Authors:  Denyo Adjoa Zakhia; Olga Voronel; Feras Zaiem; Kunil Raval; Jay Yang; Deborah Schloff; Anwar N Mohamed; Ali M Gabali
Journal:  Avicenna J Med       Date:  2019 Apr-Jun

6.  Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup.

Authors:  Elena Ciabatti; Angelo Valetto; Veronica Bertini; Maria Immacolata Ferreri; Alice Guazzelli; Susanna Grassi; Francesca Guerrini; Iacopo Petrini; Maria Rita Metelli; Maria Adelaide Caligo; Simona Rossi; Sara Galimberti
Journal:  Oncotarget       Date:  2017-03-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.